CSPC's study results of two innovative drugs selected for presentation at ESMO Congress

CSPC Pharmaceutical Group will present the latest results from clinical trials of two innovative pipeline drugs at the European Society for Medical Oncology (ESMO) Congress 2022. The Congress will be held both on-site and online in Paris from September 9 to 13,2022, bringing new hope to the treatment of cancer patients.

The ESMO Congress is Europe's most influential oncology conference, attended by more than 30,000 professionals each year. Clinicians, researchers, journalists and pharmaceutical industry representatives from around the world will attend this year's congress to share insights into the latest advances in oncology and translate science into optimal care for cancer patients.

01

Phase I/II clinical study of Duoenda® (mitoxantrone hydrochloride liposome injection) in the treatment of extranodal nasal NK/T-cell lymphoma (ENKTCL)

Selected for mini oral presentation

This study was a single-arm, open-label, multi-center phase I/II clinical trial led by Professor Huang Yunhong from The Affiliated Cancer Hospital of Guizhou Medical University. It is designed to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection in combination with pegaspargase in the treatment of ENKTCL.

About Duoenda

Duoenda® is the world's first mitoxantrone nanoliposome preparation independently developed by CSPC. The product is currently approved for treating patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). In addition to ENKTCL, for which initial data will be presented at ESMO Congress 2022, this product also shows significant efficacy in a broad spectrum of tumors, including ovarian cancer, head and neck squamous cell carcinoma, and breast cancer.

Furthermore, the use of Duoenda® in neuroinflammation is being actively explored.

02

Phase Ia study of SYHA1813, a novel VEGFR/CSF1R-targeting small molecule inhibitor, in patients with relapsed or advanced solid tumors

Selected for poster presentation

This study was an open-label, multi-center, phase I clinical study led by Professor Li Wenbin from Beijing Tiantan Hospital, Capital Medical University. The study aims to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of SYHA1813 in patients with relapsed or advanced solid tumors.

About SYHA1813

SYHA1813, a Category 1 anticancer drug candidate, is a novel VEGFR/CSF1R-targeting small molecule inhibitor with intellectual property rights in China and other countries/regions. SYHA1813 inhibits the formation of tumor neovascularization by blocking the VEGFR pathway while targeting the kinase activity of CSF1R. It can regulate the survival and proliferation of macrophages, and reshape the polarity of macrophages, demonstrating the potential for multistage tumor antagonism. In preclinical studies, SYHA1813 has shown significant anti-tumor activity against glioblastoma, kidney cancer, and colorectal cancer, presenting superior in vivo efficacy to currently approved VEGFR inhibitors.

In current clinical trials, the product has demonstrated positive anti-tumor efficacy in patients with relapsed high-grade glioma, whilst its application in other solid tumors is also under research.